Additionally, pembrolizumab in combination with enzalutamide was active in mCRPC after prior enzalutamide treatment, and the response was deep and long-lasting, without requiring tumor PD-L1 expression or DNA-repair defects (NCT02312557) [111]. This evidence concerns the gene CD274 and neoplasm.